Das Rohit R, Griesemer David A, Kothare Sanjeev V
Department of Neurology, University of Louisville, School of Medicine, Louisville, KY 40202, USA.
ISRN Neurol. 2013 Jul 1;2013:613456. doi: 10.1155/2013/613456. Print 2013.
Phenytoin (PHT) has been the most widely used medication to treat both partial and generalized seizures. However, over the past twenty years, a variety of new compounds have been released with comparable efficacy, fewer adverse effects, and more predictable pharmacokinetic properties. We surveyed neurologists and epileptologists to determine current practice patterns relating to the use of PHT using an online survey instrument. A total of 200 responses were obtained though response rates for each survey question varied. Of the respondents, 78.1% were epilepsy specialists; 60% were adult practitioners; and the remainder saw either, only children or both adults and children. For new onset partial seizures only 10 respondents said PHT would be their first or second choice, while 45% reported that they would not consider PHT. This study shows that in the era of newer medications, the role of PHT has been placed in the category of a reserve medication in intractable epilepsy.
苯妥英(PHT)一直是治疗部分性和全身性癫痫最广泛使用的药物。然而,在过去二十年中,已推出了多种新化合物,它们具有相当的疗效、更少的不良反应和更可预测的药代动力学特性。我们使用在线调查工具对神经科医生和癫痫专家进行了调查,以确定与使用PHT相关的当前实践模式。尽管每个调查问题的回复率各不相同,但总共获得了200份回复。在受访者中,78.1%是癫痫专科医生;60%是成人从业者;其余的则只看儿童患者或同时看成人和儿童患者。对于新发性部分性癫痫,只有10名受访者表示PHT会是他们的首选或次选药物,而45%的受访者表示他们不会考虑使用PHT。这项研究表明,在有更新药物的时代,PHT在难治性癫痫中的作用已被归为备用药物类别。